key: cord-0855202-w6xcwjtf
authors: Jacobson, Jennifer; Antony, Kathleen; Beninati, Michael; Alward, William; Hoppe, Kara K.
title: Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report
date: 2020-11-25
journal: Case Rep Womens Health
DOI: 10.1016/j.crwh.2020.e00273
sha: bc67483bb1f5d0b1e1dd9b9ab013768e9e1c1316
doc_id: 855202
cord_uid: w6xcwjtf

Severe infection with COVID-19 virus in pregnancy offers unique management challenges for the obstetrician and critical care specialist. We report the case of a woman at 26 weeks of gestation with acute respiratory distress syndrome secondary to COVID-19 infection treated with dexamethasone, remdesivir, convalescent plasma and mechanical ventilation. Cesarean delivery was performed at 29 weeks due to worsening maternal status. This case offers insight into the assessment and successful use of treatment strategies, including dexamethasone, remdesivir, convalescent plasma, early prone positioning, conservative fluid management, permissive hypoxia and low tidal volume parameters with ventilator support for pregnancies affected by severe COVID-19 infection.

Respiratory failure Prone Dexamethasone Acute respiratory distress syndrome (ARDS)

The mainstay of intensive care treatment for acute hypoxic respiratory failure due to severe COVID-19 infection is supportive with supplemental oxygen or invasive mechanical ventilation, judicious fluid management, systemic corticosteroids, and early use of vasoactive medications.

Patients are monitored closely for the development of viral myocarditis, thrombotic events, and superimposed bacterial pneumonia. Several experimental drug and other therapies are currently being studied, including remdesivir, lopinavir-ritonavir, tocilizumab, azithromycin, -and convalescent plasma [1, 2, 3] .

Severe infection with COVID-19 virus in pregnancy offers unique management challenges for the obstetrician and critical care specialist. Special consideration must be undertaken regarding oxygenation and respiratory support, fluid management, use of corticosteroids and experimental therapeutics, anticoagulation, and fetal monitoring, often with limited evidencebased recommendations. This case offers insight into the assessment and use of these J o u r n a l P r e -p r o o f management strategies, most specifically the use of dexamethasone and critical care strategies with early prone positioning in those requiring ventilator support. with placement in prone position, paralysis and sedation, and adjustment of ventilator settings to 6cc/kg with increased PEEP. A low tidal volume strategy was employed for lung protection in the setting of acute respiratory distress syndrome (ARDS) [4] . The patient remained in prone positioning for 16-18 hours daily to assist with ventilation [5, 6] . She received dexamethasone 20mg IV for 5 days followed by 10 mg IV for 5 days [7, 8] , remdesivir 200mg x 1 then 100mg every 24 hours for 9 days [1] , and convalescent plasma [2] on HD2. She received azithromycin and ceftriaxone for empiric treatment of possible superimposed bacterial pneumonia [3] .

Bilateral upper and lower extremity Doppler and coagulation studies were completed to assess however, overall, the infant had an uncomplicated NICU course and was discharged home on DOL 57, a postmenstrual age of 37 weeks, in good condition. With extensive discussion, we elected to administer this for the benefit of decreased morbidity among those receiving invasive respiratory treatment in COVID-19 infection, supported by both RECOVERY trial data [9] and data on use of dexamethasone in ARDS [7, 8] , as this outweighed the risk for fetal harm with prolonged corticosteroid exposure beyond the typical 4 doses of dexamethasone 6mg used for fetal lung maturity [10, 11] . One notable potential outcome for providers when considering use of dexamethasone is adrenal insufficiency in the neonate. The neonate was initially treated with hydrocortisone from DOL 1 to DOL 5 due to in utero prolonged exposure to dexamethasone; however, cortisol levels remained low at both DOL 18 (63.48 nmol/L) and DOL 56 (33.40 nmol/L), diagnosing adrenal insufficiency. This infant will require stress-dosing of steroids with any future surgery or signs of clinical illness.

Beyond low tidal volume strategies for lung protection in ARDS, a conservative fluid management approach has been demonstrated to improve lung function and shorten mechanical ventilation without an increase in non-pulmonary organ failure [15] and this was safely used in the pregnant state. Furosemide was used for fluid management and can be used in pregnancy for diuresis as needed [16] . Another point of discussion is the goal for maintenance of O2 saturations. In pregnancy, it is recommended to maintain SpO2 of 95% or greater [12, 13] and 92% or greater in non-pregnant patients, particularly with COVID-19 [14] .

In this case, permissive hypoxia to SpO2 of 90% or greater was utilized for maternal lung protection given reassuring fetal status by EFM and allowed this pre-term pregnancy to continue an additional week for fetal benefit. COVID-19 cultures were collected from the amniotic fluid and placenta at delivery and returned negative; however, it is worth noting that due to novel testing and laboratory processing procedures, these specimen sources have not yet been validated at our institution. Subsequent negative neonatal testing in this case does, however, strengthen their reliability.

Dexamethasone may provide significant maternal benefit and decrease mortality in pregnant women with severe COVID-19 infection requiring mechanical ventilation and at the same time promote fetal lung maturity. Neonatal concerns regarding its use in pregnancy include hyperglycemia with resulting neonatal hypoglycemia as well as the potential for the development of adrenal insufficiency. Generally, maternal benefit of this protocol outweighs risks of neonatal harm in the critically ill patient. None of the experimental clinical therapeutics are consider contraindicated and compassionate use of these therapeutics should be considered in pregnant women with severe illness due to COVID-19.

Compassionate use of remdesivir for patients with severe Covid-19

Convalescent plasma as a potential therapy for COVID-19

COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Does prone positioning improve oxygenation and reduce mortality in patients with acute respiratory distress syndrome?

Treatment of ARDS With Prone Positioning

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation

National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Long-term outcomes after repeat doses of antenatal corticosteroids

Respiratory Diseases in Pregnancy

Society for Maternal-Fetal Medicine. Management Considerations for Pregnant Patients With COVID-19

COVID-19 Treatment Guidelines: Oxygenation and ventilation

Comparison of two fluid-management strategies in acute lung injury

Food and Drug Administration 2020